For long-term vaccine follow-up, traditional onsite studies and newer strategies, such as tokenisation, each have unique advantages. Discover how the expected timeframe, type of data needed and study population can play ...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Responsive strategies in vaccine development
Shelley McLendon discusses the importance of disease surveillance, developments in early outbreak detection, and the role of smart data reporting and adaptive trial designs.
-
Anthrax vaccine clinical trial
This news article, first published on Contract Pharma.com, outlines how ICON has been selected by BARDA to execute an anthrax vaccine clinical trial.
-
Considerations for vaccine efficacy trials targeting emerging infectious diseases
Following the COVID-19 pandemic, Shelley McLendon outlines what lessons must be learned to prevent future other emerging infectious diseases developing on a similar scale.
This article is taken from European Biopharmaceutical Review October 2022, pages 16-18. Samedan Ltd
-
How this top CEO helped Pfizer turbocharge the covid-19 vaccine
Steve Cutler discusses ICON's covid-19 efforts, the importance of building a good team, and more in this interview with Investor's Business Daily.
-
Continuing the fight against antimicrobial resistance
Shelley Mclendon, Vice President, Vaccine and Infectious Disease, offers her insights on the necessary actions to combat the threat of AMR.
This article is taken from European Biopharmaceutical Review April 2022, pages 8-10. Samedan Ltd.
-
Combating antimicrobial resistance
Shelley McLendon, Vice President, Vaccines and Infectious Disease, discusses the use of novel diagnostics to help monitor for AMR outbreaks and reduce the overuse and misuse of antimicrobials.
-
Glycomics applications reinforce precision medicine
Nicole A. Cowan explores how glycomics is joining genomics and proteomics in the study of disease mechanisms and the development of novel therapeutics.
-
Bringing the fight to antimicrobial resistance: What COVID-19 has taught us about how to face a growing emergency
Dr. Johan Du Toit, Executive Director, Internal Medicine, considers strategies from COVID era clinical trials for addressing the public health crisis of antimicrobial resistance.
-
On the frontlines of the COVID-19 crisis
In this report, Dr Steve Cutler describes ICON’s efforts to combat the COVID-19 pandemic and how the crisis has pushed new digital technologies forward
-
The changing pace of vaccines: How COVID-19 has impacted the future of infectious disease vaccine development
Shelley McLendon considers the knock-on effect of COVID-19 for other infectious diseases, and what we can do to speed up development future vaccines
